The field of partial reprogramming is transitioning from successful mouse studies to its first human clinical trials. At the heart of this experiment lies the discovery of Yamanaka ...

St. Jude Children's Research Hospital scientists have discovered how tumors disable immune "gatekeeper" cells that alert the ...

HexemBio has launched with a seed round led by Draper Associates to advance a blood stem cell rejuvenation therapy backed by Robert Langer.

A burgeoning field is launching its first clinical trial to find out whether dialling back cell development can safely ...

EPFL researchers have uncovered how transcription factor dosage reshapes cell identity, showing that even small differences in dose can steer cells toward completely different fates. Their findings ...

Advances in iPSC technology and in vivo reprogramming are expanding the possibilities for cell therapy. Explore the science ...

For his work towards developing a novel cancer immunotherapy that turns tumors into their own vaccines, Fábio Rosa has ...

Leuven, 11 March 2025 – Solid tumors often provide a challenging environment for the T cells of our immune system. By reprogramming the metabolism of T cells, scientists at the VIB-KU Leuven Center ...

As cell therapy advances toward clinical reality, iPSC-derived cellular products, in vivo reprogramming strategies, and ...

In order to reprogram readily available cells into specific immune cells that fight various diseases, one must know the “recipe” for the transformation. Researchers at Lund University have now created ...